loading
Schlusskurs vom Vortag:
$0.296
Offen:
$0.3
24-Stunden-Volumen:
1.09M
Relative Volume:
0.40
Marktkapitalisierung:
$47.41M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.1907
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
-16.25%
1M Leistung:
-16.76%
6M Leistung:
-79.99%
1J Leistung:
-85.48%
1-Tages-Spanne:
Value
$0.281
$0.305
1-Wochen-Bereich:
Value
$0.28
$0.3581
52-Wochen-Spanne:
Value
$0.2589
$2.83

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
Firmenname
Mersana Therapeutics Inc
Name
Telefon
617-498-0020
Name
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Name
Mitarbeiter
102
Name
Twitter
@MersanaADC
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
MRSN's Discussions on Twitter

Vergleichen Sie MRSN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRSN
Mersana Therapeutics Inc
0.2861 47.41M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.19 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
544.95 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.27 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.17 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.94 28.51B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-06 Eingeleitet William Blair Outperform
2024-11-15 Fortgesetzt Citigroup Buy
2024-03-19 Hochstufung JP Morgan Underweight → Neutral
2024-02-29 Hochstufung BTIG Research Neutral → Buy
2024-02-29 Hochstufung Guggenheim Neutral → Buy
2024-02-29 Hochstufung Wedbush Neutral → Outperform
2023-12-04 Hochstufung Citigroup Neutral → Buy
2023-07-28 Herabstufung Robert W. Baird Outperform → Neutral
2023-07-27 Herabstufung BTIG Research Buy → Neutral
2023-07-27 Herabstufung Citigroup Buy → Neutral
2023-07-27 Herabstufung Guggenheim Buy → Neutral
2023-07-27 Herabstufung JP Morgan Neutral → Underweight
2023-07-27 Herabstufung Truist Buy → Hold
2023-07-27 Herabstufung Wedbush Outperform → Neutral
2023-06-16 Herabstufung JP Morgan Overweight → Neutral
2023-06-15 Eingeleitet Guggenheim Buy
2023-03-16 Hochstufung JP Morgan Neutral → Overweight
2023-01-20 Eingeleitet Citigroup Buy
2022-11-21 Eingeleitet Truist Buy
2021-10-15 Fortgesetzt BTIG Research Buy
2021-08-30 Eingeleitet H.C. Wainwright Buy
2021-03-31 Eingeleitet Credit Suisse Neutral
2020-12-03 Eingeleitet Stifel Buy
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-04-29 Eingeleitet BTIG Research Buy
2020-01-21 Bestätigt H.C. Wainwright Buy
2019-03-11 Herabstufung JP Morgan Neutral → Underweight
2018-11-14 Hochstufung Leerink Partners Mkt Perform → Outperform
2018-05-08 Eingeleitet Robert W. Baird Outperform
2018-03-19 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten

pulisher
Jun 15, 2025

94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Jun 11, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace

Jun 10, 2025
pulisher
Jun 10, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune

Jun 02, 2025
pulisher
Jun 02, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance

Jun 02, 2025
pulisher
May 27, 2025

Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada

May 27, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 26, 2025
pulisher
May 25, 2025

D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 25, 2025
pulisher
May 25, 2025

BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 25, 2025
pulisher
May 21, 2025

Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister

May 21, 2025
pulisher
May 20, 2025

Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 20, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 19, 2025
pulisher
May 19, 2025

William Blair Analysts Lift Earnings Estimates for MRSN - Defense World

May 19, 2025
pulisher
May 19, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World

May 19, 2025
pulisher
May 19, 2025

Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World

May 19, 2025
pulisher
May 18, 2025

Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World

May 18, 2025
pulisher
May 17, 2025

Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN

May 17, 2025
pulisher
May 17, 2025

Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World

May 17, 2025
pulisher
May 17, 2025

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 17, 2025
pulisher
May 16, 2025

MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Mersana Therapeutics (MRSN) Target Price Increased by Truist | M - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks

May 16, 2025
pulisher
May 16, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025
pulisher
May 16, 2025

Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria

May 16, 2025
pulisher
May 15, 2025

Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 15, 2025
pulisher
May 15, 2025

CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan

May 15, 2025

Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mandelia Ashish
VP, Chief Accounting Officer
Jan 16 '25
Sale
0.58
3,554
2,061
57,519
Protopapas Anna
Director
Jan 15 '25
Option Exercise
0.00
21,250
0
176,678
Protopapas Anna
Director
Jan 16 '25
Sale
0.58
8,637
5,009
168,041
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 15 '25
Option Exercise
0.00
19,791
0
265,721
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 16 '25
Sale
0.58
8,048
4,668
257,673
Huber Martin H. Jr.
President, CEO
Jan 15 '25
Option Exercise
0.00
11,062
0
127,389
Huber Martin H. Jr.
President, CEO
Jan 16 '25
Sale
0.58
4,514
2,618
122,875
DeSchuytner Brian
SVP, COO & CFO
Jan 15 '25
Option Exercise
0.00
20,833
0
129,863
DeSchuytner Brian
SVP, COO & CFO
Jan 16 '25
Sale
0.58
8,470
4,913
121,393
Carvajal Alejandra
SVP, Chief Legal Officer
Jan 15 '25
Option Exercise
0.00
12,500
0
83,392
$20.95
price up icon 1.46%
$36.04
price up icon 0.14%
$21.25
price down icon 0.39%
$98.93
price down icon 1.52%
$108.80
price up icon 2.21%
biotechnology ONC
$244.22
price up icon 0.68%
Kapitalisierung:     |  Volumen (24h):